EDSA · Edesa Biotech, Inc.

Performance Summary

Edesa Biotech reported a net loss of $2.2 million for the first quarter of fiscal 2026 (period ending December 31, 2025), with a loss per share of $0. The company's operating loss was $2.3 million, driven by research and development expenses of $1.1 million and general and administrative expenses of $1.2 million. Nonoperating income of $94,000 partially offset these losses, consisting primarily of $102,000 in reimbursement grant income, $47 in interest income, and a $9,000 foreign exchange loss. Net comprehensive loss totaled $2.3 million after including $5,000 in exchange differences on translation. The company's cash position improved during the quarter, with cash and cash equivalents increasing by $1.3 million to $12.1 million, supported by financing activities.

Revenue Analysis

The company did not report any revenue for the quarter. The income statement shows no revenue line items, indicating the company continues to operate as a development-stage biotechnology company without commercial product sales. The only income sources reported were nonoperating items: $102,000 in reimbursement grant income, $47 in interest income, and a $9,000 foreign exchange loss. No segment revenue breakdown or geographic revenue mix was disclosed in the provided data. The absence of revenue reflects the company's current stage of development and focus on research activities rather than commercial operations.

Margins & Profitability

With no revenue reported, traditional margin calculations (gross margin, operating margin) cannot be derived from the available data. The company reported an operating loss of $2.3 million, resulting from $2.3 million in total operating expenses ($1.1 million research and development plus $1.2 million general and administrative). The cost structure shows research and development representing approximately 48% of total operating expenses, while general and administrative represents 52%. The net loss margin relative to any revenue base cannot be calculated due to the absence of revenue figures. The company's profitability metrics remain negative as expected for a development-stage biotech company.

Cash Flow & Balance Sheet

The company used $2.1 million in cash from operating activities during the quarter, primarily driven by the $2.2 million net loss, partially offset by $25,000 in depreciation and amortization, $400,000 in share-based compensation, and working capital changes. Financing activities provided $3.4 million in cash, consisting of $3.5 million from issuance of common shares less $142,000 in issuance costs. The net change in cash was $1.3 million. The balance sheet shows total assets of $14.7 million, including $12.1 million in cash and cash equivalents, $431,000 in accounts receivable, and $2.0 million in intangible assets. Total liabilities were $756,000, all current, resulting in shareholders' equity of $14.0 million. The company's accumulated deficit reached $68.2 million.

Outlook

The filing does not contain specific forward-looking guidance, management projections, or explicit strategic priorities in the provided data. No revenue forecasts, expense projections, or specific risk factor discussions are included in the extracted financial statements. The company's continued research and development spending suggests an ongoing focus on advancing its pipeline, but no details about specific programs, timelines, or expected milestones are provided in the financial data. The improvement in cash position through equity financing indicates the company is securing funding to support operations, but no specific runway estimates or future financing plans are disclosed in the provided figures.